12.5 C
New York
Wednesday, May 25, 2022

CTI BioPharma Corp (CTIC) stock rebounded in the pre-market following financial results release.

CTI BioPharma Corp (CTIC) stock was trading 0.63% to $4.75 in the regular trading session but bounced back in the pre-market and gained 8.42% to $5.15 after the firm reported the results for the last term and fiscal year 2021. CTIC also filed forms 8-K and 10-K with the SEC on 31 March 2022. The firm also got approval for VONJO by the FDA in February 2022.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


CTI BioPharma Corp is a pharmaceutical firm, which revolves around the production, ownership, and advertising of novel assigned therapies for blood diseases. CTIC has a market cap of $459.28 million and has its base in Seattle, Washington, United States of America (USA).

What happening with CTIC?

On 31 March 2022, CTIC published the financial results for the last term and financial year 2021. The key points of the earnings are

  • The total cost and expense for operations went up by 141.4% to $35.3 million in Q4 of FY21 as compared to $14.7 million in the comparative period of last year. Also, the cost and expenses for operations grew by 99.7% in FY21 to $95.3 million versus $47.7 million in FY20.
  • CTIC had a total loss of $36.7 million in Q4 of FY21 against $15 million in Q4 of FY2020. This marks an expansion of 144.6% in the total loss. Moreover, the total loss in FY21 increased by 86.8% to $97.9 million against $53.4 million in FY20.
  • As of December 2021, the firm had cash and cash equivalents of $65.4 million. Comparatively, the cash and cash equivalents in FY2020 were $40.3 million.
  • CTI Biopharma reported a loss of $0.38 and $1.09 per stock in the last term and FY2021, respectively.

CTI BioPharma posted no sales for the period completed in December 2021, missing the expectations by 100%. This ponders to no sales in the earlier year.

Industry Outlook

The Healthcare area is vital to the presence of life and isn’t affected seriously by expansion or other emergencies like conflict. All financial exchanges endured a shot from the geopolitical emergency brought about by the Russia-Ukraine struggle while medical care stocks were impacted less. Also, given the expanded wellbeing mindfulness post-Coronavirus, stocks of health and diagnostics organizations are supposed to be bullish in the near future.

What’s next?

CTI BioPharma has beaten the market up until this point this year. one dependable measure that can assist stockholders is the organization’s earnings stance. Shareholders ought to be aware of the way that the viewpoint of the industry can affect the stock performance.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles